[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Mallon E, Hawkins D, Dinneen M, Francics N, Fearfield L, Newson R, Bunker C: Circumcision and genital dermatoses. Arch Dermatol; 2000 Mar;136(3):350-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUBJECTS: The study population consisted of 357 male patients referred for diagnosis and management of genital skin disease.
  • The control population consisted of 305 male patients without genital skin disease attending the general dermatology clinics over a 4-month period.
  • The rate of circumcision in the general male dermatology population was determined.
  • Less common diagnoses included squamous cell carcinoma (n = 4), bowenoid papulosis (n = 3), and Bowen disease (n = 3).
  • The age-adjusted odds ratio for all penile skin diseases associated with presence of the foreskin was 3.24 (95% confidence interval, 2.26-4.64).
  • All patients with Zoon balanitis, bowenoid papulosis, and nonspecific balanoposthitis were uncircumcised.
  • The presence of the foreskin may promote inflammation by a köebnerization phenomenon, or the presence of infectious agents, as yet unidentified, may induce inflammation.

  • MedlinePlus Health Information. consumer health - Circumcision.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2001 Apr;137(4):503-4 [11295938.001]
  • (PMID = 10724196.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


2. Majewski S, Marczak M, Mlynarczyk B, Benninghoff B, Jablonska S: Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol; 2005 Jan;44(1):14-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The study was performed in two cell lines: Skv human keratinocytes containing multiple integrated copies of HPV16 derived from bowenoid papulosis, and murine L1 lung sarcoma cells of Balb/c mice.
  • RESULTS: Topical application of imiquimod on the murine skin resulted in reduction of angiogenesis (P < 0.001) induced by intradermal injection of both human and mouse tumor cells, more pronounced when 5% cream was applied on three consecutive days.
  • When human Skv cells were used in angiogenesis assay, the effect of imiquimod was abolished by antibodies against IL-18 but not against TNFalpha, which may be due to overproduction of TNFalpha by Skv cells.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use
  • [MeSH-minor] Animals. Bowen's Disease / drug therapy. Bowen's Disease / virology. Cell Line, Tumor. Disease Models, Animal. Humans. Interferon-alpha / immunology. Interleukin-18 / immunology. Keratinocytes / virology. Lung Neoplasms / drug therapy. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy. Papillomaviridae / drug effects. Papillomavirus Infections / drug therapy. Sarcoma / drug therapy. Skin Neoplasms / blood supply. Skin Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / immunology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15663652.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-18; 0 / Tumor Necrosis Factor-alpha; 99011-02-6 / imiquimod
  •  go-up   go-down


3. Auepemkiate S, Thongsuksai P, Boonyaphiphat P: P16(INK4A) expression in Bowen's disease and Bowenoid papulosis. J Med Assoc Thai; 2006 Sep;89(9):1460-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P16(INK4A) expression in Bowen's disease and Bowenoid papulosis.
  • BACKGROUND: Bowen's disease (BD) is a skin carcinoma in situ occurring over the entire body surface.
  • It shares similar histopathological features with Bowenoid papulosis (BP) of the genitalia, but differs in etiology and clinical course.
  • OBJECTIVE: To evaluate the difference in p16 expression between Bowen's disease and Bowenoid papulosis.
  • MATERIAL AND METHOD: Biopsies of 46 cases of BD in the period 1994 - 2003 and 14 cases of BP during 1987 - 2003 in the Anatomical Pathology Unit, Department of Pathology, Faculty of Medicine, Prince of Songkla University, Thailand were studied by immunohistochemical methods using the P16 kit (CINTec Histology Kit, clone E6H4, Code-Nr.
  • [MeSH-major] Bowen's Disease / metabolism. Carcinoma, Squamous Cell / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Precancerous Conditions / metabolism. Skin Neoplasms / metabolism

  • Genetic Alliance. consumer health - Bowen's Disease.
  • Genetic Alliance. consumer health - Bowenoid Papulosis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100385.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


Advertisement
4. Hama N, Ohtsuka T, Yamazaki S: Detection of mucosal human papilloma virus DNA in bowenoid papulosis, Bowen's disease and squamous cell carcinoma of the skin. J Dermatol; 2006 May;33(5):331-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of mucosal human papilloma virus DNA in bowenoid papulosis, Bowen's disease and squamous cell carcinoma of the skin.
  • Human papilloma virus (HPV) is known to be an etiologic agent for benign warts of the skin.
  • In the present study, we examined the presence of mucosal HPV DNA in normal tissue, Bowen's disease (BD), Bowenoid papulosis (BP) and squamous cell carcinoma (SCC) of the skin.
  • We detected the HPV DNA with polymerase chain reactions, and identified the type by DNA sequencing.
  • Mucosal HPV, not only the epidermodysplasia verruciformis type, appear to induce malignant skin tumors.
  • [MeSH-major] Bowen's Disease / virology. Carcinoma, Squamous Cell / virology. Papillomaviridae / isolation & purification. Skin Neoplasms / virology


5. Ben M'barek L, Mebazaa A, Euvrard S, Frances C, Thervet E, Morel P, Menasché S, Legendre C, Lebbe C: 5% topical imiquimod tolerance in transplant recipients. Dermatology; 2007;215(2):130-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5% topical imiquimod tolerance in transplant recipients.
  • BACKGROUND: Topical imiquimod is a new immunomodulator agent approved for genital warts, actinic keratosis (AK) or carcinoma, occurring in immunocompetent patients.
  • OBJECTIVES: This study aimed to assess the safety and efficacy of imiquimod for the treatment of warts, AK and bowenoid papulosis (BP) in transplant patients.
  • CONCLUSIONS: Imiquimod 5% cream is a promising, well-tolerated therapy for warts, AK and BP in transplant recipients.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Immunocompromised Host. Keratosis / drug therapy. Skin Neoplasms / drug therapy. Transplantation. Warts / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Retrospective Studies. Skin / pathology. Treatment Outcome. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Warts.
  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17684375.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


6. Degener AM, Laino L, Pierangeli A, Accappaticcio G, Innocenzi D, Pala S: Human papillomavirus-32-positive extragenital Bowenoid papulosis (BP) in a HIV patient with typical genital BP localization. Sex Transm Dis; 2004 Oct;31(10):619-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-32-positive extragenital Bowenoid papulosis (BP) in a HIV patient with typical genital BP localization.
  • OBJECTIVES: Bowenoid papulosis (BP) is characterized by multiple maculopapular lesions of the genitalia; extragenital localization is rarely found.
  • Human papillomavirus (HPV) type 16 has been found in most cases of BP, but the other HPV genotypes associated with BP had been poorly characterized.
  • RESULTS: The presence of HPV-16 DNA in anogenital and HPV-32 DNA in lip lesions was demonstrated in the absence of any other HPV type and with no coinfection.
  • CONCLUSIONS: This is the first report of BP associated with HPV-32 (the causative agent of a benign hyperplasia) and a rare case of BP associated with 2 HPV types in the same patient.
  • [MeSH-major] Bowen's Disease / diagnosis. HIV Infections. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. Skin Neoplasms / diagnosis. Tumor Virus Infections / diagnosis
  • [MeSH-minor] Adult. Anal Canal. DNA Primers. DNA, Viral / analysis. Diagnosis, Differential. Female. Humans. Lip. Polymerase Chain Reaction. Vulva


7. Ruocco E, Cutrì FT, Baroni A: Bowenoid papulosis at the site of prior herpes progenitalis. Skinmed; 2004 Nov-Dec;3(6):347-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowenoid papulosis at the site of prior herpes progenitalis.
  • The obvious clinical diagnoses of genital warts on the left and Bowenoid papulosis on the right were confirmed by punch biopsies, which showed epithelial hyperplasia with diffuse cell vacuolization (koilocytes)in the left biopsy and moderate nuclear dysplasia in the right one (Figure 2).
  • Human papillomavirus phenotyping was not performed.
  • An immunomodulating treatment with imiquimod was started in the attempt to cure both the genital warts and Bowenoid papulosis lesions (imiquimod was applied three times a week for 8 weeks).
  • At the end of the treatment, the genital warts had disappeared, whereas many Bowenoid papulosis lesions were still present on the right side of the penis (Figure 3).
  • Treated with liquid nitrogen as well, the Bowenoid papulosis lesions disappeared.
  • [MeSH-major] Bowen's Disease / pathology. Herpes Genitalis / pathology. Penile Neoplasms / pathology. Precancerous Conditions / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aminoquinolines / therapeutic use. Biopsy, Needle. Drug Therapy, Combination. Follow-Up Studies. Humans. Immunohistochemistry. Male. Nitrogen / therapeutic use. Risk Assessment. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Bowenoid Papulosis.
  • MedlinePlus Health Information. consumer health - Genital Herpes.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Nitrogen, Elemental .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15538089.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 99011-02-6 / imiquimod; N762921K75 / Nitrogen
  •  go-up   go-down






Advertisement